It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prescription opioid use (POU) is often a precursor to opioid use disorder (OUD) and subsequent consequences. Persons with chronic hepatitis C virus infection (CHC) may be at a higher risk of POU due to a higher comorbidity burden and social vulnerability factors. We sought to determine the burden of POU and associated risk factors among persons with CHC in the context of social vulnerability. We identified CHC persons and propensity-score matched HCV− controls in the electronically retrieved Cohort of HCV-Infected Veterans and determined the frequency of acute, episodic long-term and chronic long-term POU and the prevalence of social vulnerability factors among persons with POU. We used logistic regression analysis to determine factors associated with POU. Among 160,856 CHC and 160,856 propensity-score matched HCV-controls, acute POU was recorded in 38.4% and 38.0% (P = 0.01) respectively. Episodic long-term POU was recorded in 3.9% in each group (P = 0.5), while chronic long-term POU was recorded in 28.4% and 19.2% (P < 0.0001). CHC was associated with a higher risk of chronic long-term POU (OR 1.66, 95%CI 1.63, 1.69), but not with acute or episodic long-term POU. Black race, female sex and homelessness were associated with a higher risk of chronic long-term POU. Presence of ≥ 1 factor was associated with a higher risk of all POU patterns. Persons with CHC have more social vulnerability factors and a higher risk of chronic long-term POU. Presence of ≥ 1 social vulnerability factor is associated with a higher risk of POU. Downstream consequences of POU need further study.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 VA Pittsburgh Healthcare System, Pittsburgh, USA (GRID:grid.413935.9) (ISNI:0000 0004 0420 3665); Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Weill Cornell Medical College, Doha, Qatar (GRID:grid.416973.e) (ISNI:0000 0004 0582 4340); Hamad Medical Corporation, Doha, Qatar (GRID:grid.413548.f) (ISNI:0000 0004 0571 546X)
2 VA Pittsburgh Healthcare System, Pittsburgh, USA (GRID:grid.413935.9) (ISNI:0000 0004 0420 3665)
3 Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
4 Hamad Medical Corporation, Doha, Qatar (GRID:grid.413548.f) (ISNI:0000 0004 0571 546X)
5 University of British Columbia, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); British Columbia Centre for Disease Control, Vancouver, Canada (GRID:grid.418246.d) (ISNI:0000 0001 0352 641X)